ALYI and KALY Shorts Double Down In Desperate Attempt To Hold On To Raging Rally; Get In Before The Buy-In
April 09 2019 - 11:57AM
InvestorsHub NewsWire
ALYI and KALY Shorts Double Down In
Desperate Attempt To Hold On To Raging Rally; Get In Before The
Buy-In
New York, NY -- April 9, 2019 --
InvestorsHub NewsWire -- www.nextbigticker.com -- The short selling against
a rally in Alternet Systems, Inc. (USOTC:
ALYI) and Kali-Extracts, Inc. (USOTC:
KALY) became apparent last week. ALYI and KALY both came
out with strong news and they’ve kept the news going with one new
development after another. ALYI and KALY have both broken
through all technical barriers and bull rallies for both rage
on. The short sellers didn’t anticipate a prolonged rally and
they’re doing their best to try and hold the rallies back.
The shorting is continuing as the short sellers double down in an
effort to halt rallies that are showing no signs of stopping any
time soon. Both ALYI and KALY indicate more big news is
coming later this month on top of the major releases they have
already put out. The ALYI and KALY short sales that continue
to make up 50% of the trading volume as reported by FINRA are bound
to run out of steam. It’s only a matter of time until short
sellers have to cover and add fuel to the rallies they failed to
stop. Get in before the buy-in.
ALYI management is in Kenya this weeking working
on a potential $20 million order for the company’s electric
motorcycles. The stock continues to react bullishly and its only a
matter of time until short sellers have to buy in to cover their
short sales.
ALYI has a 52-Week High of over $0.06 and an
analyst recommended Target PPS of $0.09. ALYI has seen a high today
of $0.05 and shows signs of bouncing back up into the $0.05 range
on its way to an analyst recommended $0.09 Target
PPS.
KALY revealed today a patented cannabis
extraction treatment for epilepsy. This is the fourth
cannabis extract treatment for a major health issue the company has
revealed in the last week. The company
currently has ongoing cannabis extract research and development
targeting four specific health issues, Chronic Obstructive
Pulmonary Disease (COPD), Type 2 Diabetes, Cancer Pain Management
and Epilepsy. KALY plans to publish an online presentation
with more detail on each of the treatment developments later this
month.
KALY Potential PPS Run From $0.01 to $0.04 On
Way To $0.10
KALY has the potential to run from its $0.01 PPS
level to $0.10 in the near term. Shortly after the 2018 Q4
acquisition of the patented cannabis extraction process, the
company PPS shot from sub-penny land to almost $0.04 on volume that
put it in the top 20 most actively traded stocks on the OTC Market.
The PPS retraced back to $0.01 and has now inched up to $0.02 in
the latest rally. With KALY’s patented cannabis pharmaceutical
research now coming to light, the PPS is positioned to shoot past
the recent $0.04 highs to a level putting it on par with some of
the other penny cannabis stock contenders. A $0.10 PPS is a
reasonable milestone following the company filing its upcoming
annual reported expected to include the company posting its first
revenue derived from its cannabis extraction process. The company
filed an extension on the 2018 annual report with the report itself
now expected within the next 15 days.
KALY is providing CBD extracts for over $1
million worth of CBD infused water produced by Puration, Inc.
(USOTC:
PURA), and KALY has also introduced its own CBD infused
gum. KALY is also implementing an extraction lab to process
biomass from Nouveau’s (USOTC:
NOUV) 100 acer hemp farm.
Following the acquisition of the patented
cannabis extraction process late last year and the corresponding
jump in price and trading volume, the OTC Markets flagged the
company in response to the jump in activity. The company has
responded by updating all its OTC Markets required reports.
Management is likely to mitigate the OTC Market’s concerns sooner
or later and see the flag removed which will likely be yet another
impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to
conduct analyst coverage of the company and file an initial analyst
report: KALY Research
Report
Disclaimer/Safe Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Alternet Systems (PK) (USOTC:ALYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alternet Systems (PK) (USOTC:ALYI)
Historical Stock Chart
From Sep 2023 to Sep 2024